Endologix (ELGX) Posts Q4 Loss of $0.26/Share; Reaffirms FY19 Revenue Forecast

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. DOX
5. CRWD
6. CHKP
7. ON
8. HNGE
9. INSP
10. SPY

Go back to Endologix (ELGX) Posts Q4 Loss of $0.26/Share; Reaffirms FY19 Revenue Forecast

Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results

February 25, 2019 4:01 PM EST

IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (the Company) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December31, 2018.

Global revenue in the fourth quarter of 2018 was $34.7 million, a 21.2% decrease from $44.0 million in the fourth quarter of 2017. For the year ended December31, 2018, global revenue was $156.5 million, a 13.6% decrease from $181.2 million a year ago.

Our performance in the fourth quarter and second half of the year reinforces confidence in our strategic planning process and our ability to implement improvements. The... More